Hanall Biopharma Co., Ltd.
Research Hanall Biopharma Co., Ltd. (009420.KS) on Bullrun: market cap KRW 2.50T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker009420.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 2.50T
- Financial periodQ2 2026
- RevenueKRW 44.28B
- Net income-KRW 19.23B
- Free cash flow-KRW 8.68B
- Gross margin56.0%
Valuation Snapshot
latest market cap is KRW 2.50T.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | KRW 2.50T | n/a | n/a | n/a |
Dividend history
About Hanall Biopharma Co., Ltd.
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally.
ETFs that hold Hanall Biopharma Co., Ltd.
US-listed ETFs
Hanall Biopharma Co., Ltd. is held by 18 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI Emerging Markets ETF (IEMG) | 0.01% | 0.09% |
| Vanguard FTSE Developed Markets Index Fund ETF Shares (VEA) | <0.01% | 0.03% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| iShares Core MSCI Total International Stock ETF (IXUS) | <0.01% | 0.07% |
| State Street SPDR Portfolio Developed World ex-US ETF (SPDW) | 0.01% | 0.03% |
| Vanguard FTSE Pacific Index Fund ETF Shares (VPL) | 0.01% | 0.07% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.03% | 0.06% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hanall Biopharma Co., Ltd.'s market cap?
Hanall Biopharma Co., Ltd.'s market capitalization is KRW 2.50T.
What does Hanall Biopharma Co., Ltd. do?
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally.